Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Lyra Therapeutics management to meet virtually with Cantor Fitzgerald » 04:55
10/20/22
10/20
04:55
10/20/22
04:55
LYRA

Lyra Therapeutics

$4.85 /

+0.05 (+1.04%)

Virtual Meeting to be…

Virtual Meeting to be held on October 20 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$4.85 /

+0.05 (+1.04%)

LYRA Lyra Therapeutics
$4.85 /

+0.05 (+1.04%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$4.85 /

+0.05 (+1.04%)

LYRA Lyra Therapeutics
$4.85 /

+0.05 (+1.04%)

LYRA Lyra Therapeutics
$4.85 /

+0.05 (+1.04%)

Conference/Events
Lyra Therapeutics management to meet virtually with Cantor Fitzgerald » 17:05
10/14/22
10/14
17:05
10/14/22
17:05
LYRA

Lyra Therapeutics

$4.80 /

-0.045 (-0.93%)

Virtual Meeting to be…

Virtual Meeting to be held on October 20 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$4.80 /

-0.045 (-0.93%)

LYRA Lyra Therapeutics
$4.80 /

-0.045 (-0.93%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$4.80 /

-0.045 (-0.93%)

LYRA Lyra Therapeutics
$4.80 /

-0.045 (-0.93%)

LYRA Lyra Therapeutics
$4.80 /

-0.045 (-0.93%)

Conference/Events
Lyra Therapeutics management to meet virtually with Cantor Fitzgerald » 04:55
10/04/22
10/04
04:55
10/04/22
04:55
LYRA

Lyra Therapeutics

$5.31 /

+0.305 (+6.10%)

Biotech Analyst Chen…

Biotech Analyst Chen holds a two day virtual meeting with President & CEO Palasis and CFO Cavalier, October 3-4 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$5.31 /

+0.305 (+6.10%)

LYRA Lyra Therapeutics
$5.31 /

+0.305 (+6.10%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$5.31 /

+0.305 (+6.10%)

LYRA Lyra Therapeutics
$5.31 /

+0.305 (+6.10%)

LYRA Lyra Therapeutics
$5.31 /

+0.305 (+6.10%)

Conference/Events
Lyra Therapeutics management to meet virtually with Cantor Fitzgerald » 04:55
10/03/22
10/03
04:55
10/03/22
04:55
LYRA

Lyra Therapeutics

$5.16 /

+0.16 (+3.20%)

Biotech Analyst Chen…

Biotech Analyst Chen holds a two day virtual meeting with President & CEO Palasis and CFO Cavalier, October 3-4 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$5.16 /

+0.16 (+3.20%)

LYRA Lyra Therapeutics
$5.16 /

+0.16 (+3.20%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$5.16 /

+0.16 (+3.20%)

LYRA Lyra Therapeutics
$5.16 /

+0.16 (+3.20%)

LYRA Lyra Therapeutics
$5.16 /

+0.16 (+3.20%)

Conference/Events
Lyra Therapeutics management to meet virtually with Cantor Fitzgerald » 17:26
09/27/22
09/27
17:26
09/27/22
17:26
LYRA

Lyra Therapeutics

$5.06 /

+ (+0.00%)

Biotech Analyst Chen…

Biotech Analyst Chen holds a two day virtual meeting with President & CEO Palasis and CFO Cavalier, October 3-4 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$5.06 /

+ (+0.00%)

LYRA Lyra Therapeutics
$5.06 /

+ (+0.00%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$5.06 /

+ (+0.00%)

LYRA Lyra Therapeutics
$5.06 /

+ (+0.00%)

LYRA Lyra Therapeutics
$5.06 /

+ (+0.00%)

Conference/Events
Lyra Therapeutics management to meet virtually with William Blair » 04:55
09/22/22
09/22
04:55
09/22/22
04:55
LYRA

Lyra Therapeutics

$5.70 /

-0.1 (-1.72%)

Virtual Meeting to be…

Virtual Meeting to be held on September 22 hosted by William Blair.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$5.70 /

-0.1 (-1.72%)

LYRA Lyra Therapeutics
$5.70 /

-0.1 (-1.72%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$5.70 /

-0.1 (-1.72%)

LYRA Lyra Therapeutics
$5.70 /

-0.1 (-1.72%)

LYRA Lyra Therapeutics
$5.70 /

-0.1 (-1.72%)

Conference/Events
Lyra Therapeutics management to meet virtually with William Blair » 15:09
09/19/22
09/19
15:09
09/19/22
15:09
LYRA

Lyra Therapeutics

$5.98 /

+0.08 (+1.36%)

Virtual Meeting to be…

Virtual Meeting to be held on September 22 hosted by William Blair.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$5.98 /

+0.08 (+1.36%)

LYRA Lyra Therapeutics
$5.98 /

+0.08 (+1.36%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$5.98 /

+0.08 (+1.36%)

LYRA Lyra Therapeutics
$5.98 /

+0.08 (+1.36%)

LYRA Lyra Therapeutics
$5.98 /

+0.08 (+1.36%)

Hot Stocks
Lyra Therapeutics doses first patient in Phase 2 rhinosinusitis trial » 07:04
09/13/22
09/13
07:04
09/13/22
07:04
LYRA

Lyra Therapeutics

$6.15 /

+ (+0.00%)

Lyra Therapeutics…

Lyra Therapeutics announced that the first patients have been treated in Part 2, the randomized stage, of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis - CRS - who have had a prior sinus surgery. LYR-220 has been specifically designed to deliver six months of continuous anti-inflammatory medication in a controlled and consistent fashion to the sinonasal passages for CRS patients that continue to require treatment despite prior surgical treatment. The Phase 2 BEACON trial is to evaluate safety, tolerability, and pharmacokinetics of LYR-220 matrix, over a 24-week period, in symptomatic adult CRS patients who have had a prior bilateral sinus surgery. In the Part 1 stage, six patients received the LYR-220 matrix implant, demonstrating the feasibility and tolerability of LYR-220 placement bilaterally in this patient population. No serious or unexpected product related adverse events have been reported. Although efficacy evaluation is not the objective during the uncontrolled Part 1 stage of the trial, there was a mean improvement of 21 points - 37% - from baseline in the Sino-nasal Outcome Test total score, greater than twice the minimal clinically important difference of 8.9 points. The company anticipates completing enrollment for the full Phase 2 BEACON trial around year-end.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$6.15 /

+ (+0.00%)

LYRA Lyra Therapeutics
$6.15 /

+ (+0.00%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$6.15 /

+ (+0.00%)

LYRA Lyra Therapeutics
$6.15 /

+ (+0.00%)

LYRA Lyra Therapeutics
$6.15 /

+ (+0.00%)

Hot Stocks
Lyra announces additional data presentations from Phase 2 LANTERN study » 13:28
09/10/22
09/10
13:28
09/10/22
13:28
LYRA

Lyra Therapeutics

$6.15 /

-0.01 (-0.16%)

Lyra Therapeutics…

Lyra Therapeutics announced that new LYR-210 data analyses from the Phase 2 LANTERN study will be presented today at the 68th Annual Meeting of the American Rhinologic Society in Philadelphia. The additional results from the previously-reported Phase 2 LANTERN study showed that LYR-210 significantly improved symptom severity from baseline of 3 cardinal symptoms of chronic rhinosinusitis - nasal blockage, nasal discharge, and facial pain/pressure - when assessed in a responder analysis as individual and composite symptom scores at week 24. Compared to control, significantly higher proportions of LYR-210-treated subjects improved from moderate or severe at baseline to mild or none at week 24 in nasal blockage, nasal discharge, and facial pain/pressure. Consistent with other reported data from the LANTERN study, LYR-210 demonstrated a dose-dependent response in the 3CS severity analysis. A second oral presentation for LYR-210 at the ARS meeting will highlight the correlation between the 3CS composite scores and Sino-Nasal Outcome Test scores. The data show that the clinical changes in CRS patients measured in the 3CS composite score strongly and significantly correlate with the change in SNOT-22 total score, based on data evaluated at week 24 in the LANTERN study. Both assessments, 3CS and SNOT-22, provide critical information on a patient's response to treatment and the impact CRS has on quality of life.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$6.15 /

-0.01 (-0.16%)

LYRA Lyra Therapeutics
$6.15 /

-0.01 (-0.16%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$6.15 /

-0.01 (-0.16%)

LYRA Lyra Therapeutics
$6.15 /

-0.01 (-0.16%)

LYRA Lyra Therapeutics
$6.15 /

-0.01 (-0.16%)

Hot Stocks
Lyra announces first patient enrolled in ENLIGHTEN II trial of LYR-210 » 07:15
09/08/22
09/08
07:15
09/08/22
07:15
LYRA

Lyra Therapeutics

$6.05 /

-0.07 (-1.14%)

Lyra Therapeutics…

Lyra Therapeutics announced the enrollment of the first patient in the Phase 3 ENLIGHTEN II clinical trial of LYR-210 in adult patients with chronic rhinosinusitis, CRS. LYR-210 is designed as an alternative to sinus surgery for the millions of CRS patients that remain symptomatic despite treatment. ENLIGHTEN II is the second Phase 3 trial in the pivotal clinical program for LYR-210, along with the ENLIGHTEN I trial that was initiated earlier this year. The two ENLIGHTEN trials will enroll surgically-naive CRS patients in the U.S. and Europe to support a New Drug Application to the U.S. Food and Drug Administration for LYR-210. "We are excited about the ENLIGHTEN pivotal program, with both Phase 3 trials now actively enrolling patients," said Maria Palasis, Ph.D., President and Chief Executive Officer of Lyra Therapeutics. "LYR-210 is the first CRS product candidate designed to provide six months of continuous therapy with a single treatment, and we are focused on the opportunity to bring a new standard of care to the millions of CRS patients suffering with the disease."

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$6.05 /

-0.07 (-1.14%)

LYRA Lyra Therapeutics
$6.05 /

-0.07 (-1.14%)

05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
05/24/22 Cantor Fitzgerald
Lyra Therapeutics initiated with an Overweight at Cantor Fitzgerald
LYRA Lyra Therapeutics
$6.05 /

-0.07 (-1.14%)

LYRA Lyra Therapeutics
$6.05 /

-0.07 (-1.14%)

LYRA Lyra Therapeutics
$6.05 /

-0.07 (-1.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.